ERBB2 and colorectal carcinoma: A study analyzing ctDNA in 47 evaluable plasma samples enrolled in the HERACLES trial found HER2 amplification in 46 samples, yielding a sensitivity of 97.9% for identifying HER2-positive CRC [30].